The company had hoped its antibody drug conjugate could help frail and elderly B-cell lymphoma patients ineligible for chemotherapy, but the trial will now close following patient deaths.
ADC Therapeutics is to end a Phase II study of its antibody-drug conjugate Zynlonta in unfit or frail patients with previously untreated diffuse large B-cell lymphoma, after concluding the risks of the trial outweighed benefits.
That came after 12 patients out of 40 enrolled on the LOTIS-09 study died, including seven respiratory event-related deaths. The...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
